_15_11zon.webp)
7 HealthTech Stocks Trending Now BIIB stock, PRTA stock, ILMN stock, OCUL stock, PHAS stock, AQST stock, XFOR stock
Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at finmarketnews.com, will continue to monitor these healthtech companies to see if the momentum continues. FinMarketNews.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent BIIB Stock Price: $276.61
Summary: Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Phil Nadeau analyst at Cowen & Co. reiterates coverage on Biogen (BIIB) stock in the energy sector with a Buy rating and has set BIIB's stock price target at $ 270.
TipRanks.com reports that Biogen currently has 24 analysts offering 12-month price targets on BIIB and the consensus is a Moderate Buy rating with an average stock price target of $258.35. The most recent BIIB stock price we have is $276.61 and we are not making any BIIB forecasts at this time.
In addition, TradingView issued a n/a rating for BIIB over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BIIB. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BIIB, please click here >>
Prothena, PRTA
Recent PRTA Stock Price: $58
Summary: Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A'.'Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
Kennen MacKay analyst at RBC Capital reiterates coverage on Prothena (PRTA) stock in the energy sector with a Buy rating and has set PRTA's stock price target at $ 52.
TipRanks.com reports that Prothena currently has 6 analysts offering 12-month price targets on PRTA and the consensus is a Strong Buy rating with an average stock price target of $68.83. The most recent PRTA stock price we have is $58 and we are not making any PRTA forecasts at this time.
In addition, TradingView issued a n/a rating for PRTA over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on PRTA. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on PRTA, please click here >>
Illumina, ILMN
Recent ILMN Stock Price: $201.29
Summary: Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts.
Vijay Kumar analyst at Evercore ISI reiterates coverage on Illumina (ILMN) stock in the energy sector with a Buy rating and has set ILMN's stock price target at $ 250.
TipRanks.com reports that Illumina currently has 15 analysts offering 12-month price targets on ILMN and the consensus is a Hold rating with an average stock price target of $250.36. The most recent ILMN stock price we have is $201.29 and we are not making any ILMN forecasts at this time.
In addition, TradingView issued a n/a rating for ILMN over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ILMN. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ILMN, please click here >>
Ocular Therapeutix, OCUL
Recent OCUL Stock Price: $4.13
Summary: Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.
Yi Chen analyst at H.C. Wainwright reiterates coverage on Ocular Therapeutix (OCUL) stock in the energy sector with a Buy rating and has set OCUL's stock price target at $ 10.
TipRanks.com reports that Ocular Therapeutix currently has 4 analysts offering 12-month price targets on OCUL and the consensus is a Strong Buy rating with an average stock price target of $15.00. The most recent OCUL stock price we have is $4.13 and we are not making any OCUL forecasts at this time.
In addition, TradingView issued a n/a rating for OCUL over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on OCUL. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on OCUL, please click here >>
Phasebio Pharmaceuticals, PHAS
Recent PHAS Stock Price: $0.257
Summary: PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States.
Annabel Samimy analyst at Stifel Nicolaus reiterates coverage on Phasebio Pharmaceuticals (PHAS) stock in the energy sector with a Hold rating and has set PHAS's stock price target at $ 1.
TipRanks.com reports that Phasebio Pharmaceuticals currently has 4 analysts offering 12-month price targets on PHAS and the consensus is a Hold rating with an average stock price target of $9.50. The most recent PHAS stock price we have is $0.257 and we are not making any PHAS forecasts at this time.
In addition, TradingView issued a n/a rating for PHAS over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on PHAS. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on PHAS, please click here >>
Aquestive Therapeutics, AQST
Recent AQST Stock Price: $1.16
Summary: Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States.
Jason Butler analyst at JMP Securities reiterates coverage on Aquestive Therapeutics (AQST) stock in the energy sector with a Buy rating and has set AQST's stock price target at $ 7.
TipRanks.com reports that Aquestive Therapeutics currently has 4 analysts offering 12-month price targets on AQST and the consensus is a Strong Buy rating with an average stock price target of $6.50. The most recent AQST stock price we have is $1.16 and we are not making any AQST forecasts at this time.
In addition, TradingView issued a n/a rating for AQST over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on AQST. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on AQST, please click here >>
X4 Pharmaceuticals, XFOR
Recent XFOR Stock Price: $1.45
Summary: X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States.
Swayampakula Ramakanth analyst at H.C. Wainwright reiterates coverage on X4 Pharmaceuticals (XFOR) stock in the energy sector with a Buy rating and has set XFOR's stock price target at $ 3.5.
TipRanks.com reports that X4 Pharmaceuticals currently has 5 analysts offering 12-month price targets on XFOR and the consensus is a Strong Buy rating with an average stock price target of $5.50. The most recent XFOR stock price we have is $1.45 and we are not making any XFOR forecasts at this time.
In addition, TradingView issued a n/a rating for XFOR over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on XFOR. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on XFOR, please click here >>
The editors at finmarketnews.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinMarketNews.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinMarketNews.com.
==============================================================================